Butyrate/Hexanoate in Metabolic Health

Not Applicable

Completed

• Conditions: Metabolic Disease
• Interventions: Dietary Supplement: butyrate and hexanoate amount 3; Dietary Supplement: butyrate and hexanoate amount 1; Dietary Supplement: butyrate and hexanoate amount 2; Dietary Supplement: Placebo

• Registration Number: NCT04662411
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

In this study, we aim to identify a well consumable butyrate/hexanoate-enriched oil that increases circulating SCFA concentrations and improves postprandial substrate metabolism, which could be further used for a long-term study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-12-04
• Study First Submitted QC: 2020-12-04
• Study First Posted: 2020-12-10
• Study Start: 2021-01-13
• Primary Completion: 2021-07-26
• Study Completion: 2021-07-26
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-26
• Last Update Posted: 2021-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 14

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
butyrate and hexanoate amount 3	butyrate and hexanoate amount 3	-
butyrate and hexanoate amount 1	butyrate and hexanoate amount 1	1325 mg of butyrate and hexanoate
butyrate and hexanoate amount 2	butyrate and hexanoate amount 2	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Plasma butyrate concentrations	Fasting and postprandial butyrate will be measured before and up to 6 hours after intake of the supplement	Plasma butyrate concentrations

Secondary Outcome Measures

Name	Time	Method
Circulating insulin	Fasting and postprandial insulin will be measured before and up to 6 hours after intake of the supplement	Circulating . insulin will be assessed in plasma
Breath H2	Fasting and postprandial breath H2 will be measured before and up to 6 hours after intake of the supplement	Breath H2 using Gastrolyzer
Circulating Free Fatty Acids	Fasting and postprandial Free Fatty Acids will be measured before and up to 6 hours after intake of the supplement	Circulating Free Fatty Acids assessed in plasma
Circulating Glycerol	Fasting and postprandial Glycerol will be measured before and up to 6 hours after intake of the supplement	Circulating Glycerol assessed in plasma
Circulating Glucose	Fasting and postprandial glucose will be measured before and up to 6 hours after intake of the supplement	Circulating Glucose assessed in plasma
Circulating Triglycerides (TG)	Fasting and postprandial TG will be measured before and up to 6 hours after intake of the supplement	Circulating Triglycerides assessed in plasma

Trial Locations

Locations (1)

Maastricht University Medical Centre; 🇳🇱 Maastricht, Netherlands